STOCK TITAN

FINDIT (FDIT) Stock News

FDIT OTC
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.86%
Tags
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
38.92%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.65%
Tags
-
Rhea-AI Summary

BioRegenx, Inc. has announced a new peer-reviewed study published in Pediatric Critical Care Medicine, focusing on glycocalyx biomarkers in children with sepsis. The study, conducted by Jaime Fernández-Sarmiento and colleagues, utilized the GlycoCheck™ system to assess the impact of unbalanced and balanced crystalloids on the endothelial glycocalyx. Findings revealed that unbalanced fluids lead to glycocalyx degradation, heightening risks of vascular permeability and kidney failure. The GlycoCheck system, FDA registered, has been featured in over 100 studies and is crucial for monitoring microvascular health. Ongoing studies are further evaluating their Endocalyx Pro™ supplement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
none
Rhea-AI Summary

BioRegenx, Inc. and Findit, Inc. have announced a merger agreement as BioRegenx reveals a new peer-reviewed study on
Endocalyx Pro™ in the International Journal of Molecular Sciences. The research indicates that Endocalyx Pro
restores and protects the endothelial glycocalyx in kidney patients exposed to toxic hemodialysis plasma. Damage to
this glycocalyx is linked to increased cardiovascular risks among Chronic Kidney Disease patients. The study indicates
Endocalyx Pro can prevent glycocalyx damage and shows effective results in mouse models. The product is patented and
distributed by Microvascular Health Solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.46%
Tags
none
-
Rhea-AI Summary

Findit, Inc. (OTC PINK:FDIT) has announced a merger with BioRegenx, Inc., approved by both boards, expected to close in Q1 2023, pending regulatory approval. This deal results in BioRegenx controlling 90% of Findit’s voting securities, with significant stock exchanges occurring. A reverse stock split of 1 for 25 is planned to attract institutional investors. BioRegenx, focusing on regenerative healthcare, aims to enhance Findit's marketing and product offerings, leveraging its subsidiaries and patented technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
56.52%
Tags
-
News
Rhea-AI Summary

Findit, Inc. (OTC PINK:FDIT) has updated its Investor Relations page to assist investors in transferring paper certificates to Book-Entry shares, following their recent switch to Clear Trust as their Transfer Agent. Secretary Tom Powers invites inquiries directly and emphasizes ongoing efforts in company growth, including technology enhancements and new client acquisition, alongside the preparation of quarterly reports and a forthcoming Shareholder update. Findit.com, the company's social media platform, enables enhanced brand visibility through content management and indexing in major search engines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Findit, Inc. (OTC PINK:FDIT) announced a new partnership with Rentalz.com, a vacation rental marketplace under Resortia Group. Rentalz differentiates itself by collaborating solely with professional property managers and not charging guest booking fees, allowing guests to save an average of 10% compared to major competitors like Airbnb and VRBO. The platform boasts around 50,000 listings nationwide and aims for rapid expansion. Findit will aid in enhancing Rentalz's web presence through SEO and content services, targeting improved traffic without incurring high Pay-Per-Click costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.01%
Tags
none

FAQ

What is the current stock price of FINDIT (FDIT)?

The current stock price of FINDIT (FDIT) is $0.03315 as of February 7, 2025.